Optimism that human embryonic stem cells (hESC) would provide a virtually unlimited source of selected cell types for future cell therapies, as well as drug screening and development, has resulted in a considerable progress in stem cell biology over nearly two decades since the first hESC were derived 1. However, the controversy over the use of ..
Cedars-Sinai, UCSF Experts Steer the Development of Stem Cells to Regenerate and Repair Organs Cedars-Sinai
Stem cells head to the clinic: treatments for cancer, diabetes and Parkinsons disease could soon be here Nature.com
Scientists steer the development of stem cells to regenerate and repair organs Phys.org
Scientists reprogram elephant stem cells to revive the woolly mammoth The Brighter Side of News
Timely TGF signalling inhibition induces notochord Nature.com
Human embryonic stem cells, or hESCs, enable scientists to study early human developmental processes that would otherwise be inaccessible, gain critical insights into diseases and develop new treatment strategies that could one day transform into life-saving therapies. Researchers investigate the mechanisms underlying the differentiation The process by which stem cells transform into specific, specialized cell types with distinct functions and features. differentiation The process by which stem cells transform into specific, specialized cell types with distinct functions and features. of hESCs into distinct cell types with the aim of replicating this process in a lab dish. Our investigators are pursuing methods to cultivate specific cell types that can be used in cell therapies for a range of conditions including heart failure, neurodegenerative diseases, muscular dystrophies and spinal cord injuries.
During the 25th International AIDS Conference (AIDS 2024), being held in Munich, Germany, a new case of long HIV remission was reported and fuels optimism for an eventual HIV cure. In 2007, Timothy Brown, the so-called first Berlin patient, was the first person to be considered cured of HIV. He underwent a stem cell transplant to treat leukaemia from a donor carrying a rare genetic mutation CCR5-delta32, which is known to provide genetic resistance to HIV making his reconstituted immune cells (CD4 cells) unable to be infected with HIV. Although Timothy died due to recurrent leukaemia in 2020, the success of his treatment has led to four other people following similar treatments and being in sustained remission
The International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1107 reported the first case of HIV cure in a woman living with HIV submitted to a dual stem cell transplant (i.e., an umbilical cord blood transplant combined with a half-matched bone marrow transplant) for treatment of an acute myelogenous leukemia. The IMPAACT P1107 researchers presented the case details during the oral abstract session held at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022). The study participant is a woman from New York (USA) who stopped antiretroviral therapy (ART) at 37 months post-transplant and has had no HIV detected for 14 months. The dual stem cell therapy also led to remission from leukemia that she developed in 2017. The IMPAACT P1107 is an observational study that aims to describe the outcomes in people living with HIV who undergo a transplantation with cord blood stem cells with a CCR5 genetic mutation for treatment of cancer, hematopoietic disease, or other underlying disease
Two new companion reports released today by the World Health Organization (WHO) provide the first global recommendations to help establish human genome editing as a tool for public health, with an emphasis on safety, effectiveness and ethics. The forward-looking new reports result from the first broad, global consultation looking at somatic, germline and heritable human genome editing. The consultation, which spanned over two years, involved hundreds of participants representing diverse perspectives from around the world, including scientists and researchers, patient groups, faith leaders and indigenous peoples. Human genome editing has the potential to advance our ability to treat and cure disease, but the full impact will only be realized if we deploy it for the benefit of all people, instead of fueling more health inequity between and within countries, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
Recent Comments